# Next-generation human liver gene therapy

> **NIH NIH DP1** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2021 · $785,554

## Abstract

Project Summary/Abstract
Pioneering clinical trials of hepatocyte-targeted liver gene therapy in hemophilias have established the principal
therapeutic efficacy of adenoassociated virus (AAV) vectors. Clinical trials have also revealed limitations of
current AAV vectors, mainly lower than expected therapeutic efficacy and dose-dependent toxicity undermining
both safety and efficacy. These clinical findings show that animal models, even monkeys or mice engrafted
with human hepatocytes, fail to accurately predict the performance of AAV vectors in humans. The limitations
of current AAV vectors need to be overcome for broad application of AAV liver gene therapy because most
liver diseases require more hepatocytes to be transduced to achieve a therapeutic effect than hemophilias. To
maximize the therapeutic effect that can be achieved within a safe AAV vector dose limit, we will identify AAV
capsids that transduce hepatocytes in the human liver with maximum efficiency but no or limited off-targeting.
For this, we will harness the near-clinical conditions provided by normothermic machine perfusion (NMP) of
human livers. We will compare capsids currently used in clinical trials of liver gene therapy to engineered
capsids reported to efficiently target mouse liver or human hepatocytes engrafted in mice. To compare capsids
side by side, we have established analysis of AAV vector-expressed barcodes by single-cell RNA sequencing
of comprehensive cell populations isolated from human livers after NMP. We will also target capsids de novo in
human livers maintained by NMP by screening a library of 1 million chimeric capsids generated by shuffling of
the DNA sequences of naturally occurring AAV capsids. In addition to achieving unprecedented levels of
efficiency and specificity of transduction of hepatocytes, we aim to establish transduction of cholangiocytes,
thereby facilitating the development of gene therapies for biliary diseases. We will also target activated hepatic
stellate cells (myofibroblasts), the source of excessive collagen in liver fibrosis, and reactive cholangiocytes,
which form the ductular reaction characteristic for cholestatic liver diseases. Efficient and specific in vivo gene
delivery to these pathogenic and abundant cells will facilitate therapeutic strategies based on inactivation or
repurposing, for example, reprogramming into hepatocytes. By identifying or generating capsids that transduce
hepatocytes and other therapeutically relevant liver cell types with the highest level of efficiency and specificity
our results will directly inform clinical trials that are at the planning stage and provide the basis for extending
the reach of AAV liver gene therapy to common liver diseases like fatty liver disease and biliary diseases,
including liver fibrosis as their common end stage.

## Key facts

- **NIH application ID:** 10326762
- **Project number:** 1DP1DK130689-01
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Holger Willenbring
- **Activity code:** DP1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $785,554
- **Award type:** 1
- **Project period:** 2021-09-30 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10326762

## Citation

> US National Institutes of Health, RePORTER application 10326762, Next-generation human liver gene therapy (1DP1DK130689-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10326762. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*